Skip to main content
NewslettersWatchlist

Tracon Pharmaceuticals Inc(TCON-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.4201
Day High1.5800
Open:1.5800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Globe Newswire
TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
Globe Newswire
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Globe Newswire
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
Globe Newswire
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
Globe Newswire
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
Globe Newswire
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Globe Newswire
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
Globe Newswire
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
InvestorPlace
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Globe Newswire
TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference
Globe Newswire
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Globe Newswire
TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Globe Newswire
TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol
Globe Newswire
TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022
Globe Newswire
TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute
Globe Newswire
TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Globe Newswire
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
Globe Newswire
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
Globe Newswire
TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference
Globe Newswire
TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Globe Newswire
TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021
Globe NewsWire
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Globe NewsWire
TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
Globe NewsWire
TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
Globe NewsWire
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Globe NewsWire
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
Globe NewsWire
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

Profile

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.